9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation



Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Estimated reading time: < 1 min


Solid Tumor|Lymphoma

Estimated Enrollment: 121

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: PXD101-CLN-9

Study First Received: December 18, 2006

Last Updated: July 7, 2015

Estimated Primary Completion Date: August 2011

Primary Outcome Measures:

Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort|Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels|Explore anti-tumor activity|Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma

Sponsors and Collaborators:

Onxeo|Spectrum Pharmaceuticals, Inc

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT00413075

Was this article helpful?
Views: 71